JP7289029B2 - 分子誘導システムペプチド及びその使用 - Google Patents

分子誘導システムペプチド及びその使用 Download PDF

Info

Publication number
JP7289029B2
JP7289029B2 JP2020501210A JP2020501210A JP7289029B2 JP 7289029 B2 JP7289029 B2 JP 7289029B2 JP 2020501210 A JP2020501210 A JP 2020501210A JP 2020501210 A JP2020501210 A JP 2020501210A JP 7289029 B2 JP7289029 B2 JP 7289029B2
Authority
JP
Japan
Prior art keywords
mgs
seq
peptides
peptide
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020501210A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020535110A (ja
Inventor
キャスリン シー ブラウン
ネイサン コリンズ
シュンジ スーザン リー
カーティス オールレッド
キーン チュン
マイケル マグワイア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SRI International Inc
Original Assignee
SRI International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SRI International Inc filed Critical SRI International Inc
Publication of JP2020535110A publication Critical patent/JP2020535110A/ja
Priority to JP2023062195A priority Critical patent/JP7642700B2/ja
Application granted granted Critical
Publication of JP7289029B2 publication Critical patent/JP7289029B2/ja
Priority to JP2025028474A priority patent/JP2025081638A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/05—Fusion polypeptide containing a localisation/targetting motif containing a GOLGI retention signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
JP2020501210A 2017-07-10 2018-07-10 分子誘導システムペプチド及びその使用 Active JP7289029B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023062195A JP7642700B2 (ja) 2017-07-10 2023-04-06 分子誘導システムペプチド及びその使用
JP2025028474A JP2025081638A (ja) 2017-07-10 2025-02-26 分子誘導システムペプチド及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762530633P 2017-07-10 2017-07-10
US62/530,633 2017-07-10
PCT/US2018/041403 WO2019014190A1 (en) 2017-07-10 2018-07-10 MOLECULAR GUIDANCE SYSTEM PEPTIDES AND USES THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023062195A Division JP7642700B2 (ja) 2017-07-10 2023-04-06 分子誘導システムペプチド及びその使用

Publications (2)

Publication Number Publication Date
JP2020535110A JP2020535110A (ja) 2020-12-03
JP7289029B2 true JP7289029B2 (ja) 2023-06-09

Family

ID=65002631

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020501210A Active JP7289029B2 (ja) 2017-07-10 2018-07-10 分子誘導システムペプチド及びその使用
JP2023062195A Active JP7642700B2 (ja) 2017-07-10 2023-04-06 分子誘導システムペプチド及びその使用
JP2025028474A Pending JP2025081638A (ja) 2017-07-10 2025-02-26 分子誘導システムペプチド及びその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023062195A Active JP7642700B2 (ja) 2017-07-10 2023-04-06 分子誘導システムペプチド及びその使用
JP2025028474A Pending JP2025081638A (ja) 2017-07-10 2025-02-26 分子誘導システムペプチド及びその使用

Country Status (6)

Country Link
US (3) US11965004B2 (https=)
EP (1) EP3652196A4 (https=)
JP (3) JP7289029B2 (https=)
CN (2) CN111278847B (https=)
AU (3) AU2018301804B2 (https=)
WO (1) WO2019014190A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11965004B2 (en) 2017-07-10 2024-04-23 Sri International Molecular guide system peptides and uses thereof
CN118240025A (zh) 2017-07-10 2024-06-25 斯坦福国际研究院 用于治疗癌症的肽皂草素缀合物
US20220380764A1 (en) * 2019-10-01 2022-12-01 Sri International Molecular guide system peptides and uses thereof
US20230364261A1 (en) * 2020-09-21 2023-11-16 Sri International Targeted antigen delivery system and uses thereof
WO2025106488A1 (en) * 2023-11-13 2025-05-22 Sri International Lung fibroblast-specific molecular guidance system peptides and uses thereof
CN118440159A (zh) * 2024-04-28 2024-08-06 中国人民解放军海军军医大学第二附属医院 一种预防或治疗心肌缺血再灌注损伤的多肽及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7671010B2 (en) 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
WO2004003170A2 (en) 2002-06-28 2004-01-08 The Johns Hopkins University Agents capable of inhibiting ras and uses thereof
JP2006521088A (ja) * 2002-11-15 2006-09-21 メディカル リサーチ カウンシル 抗活性化ｒａｓ抗体
CA2524124C (en) 2003-04-30 2014-03-25 Uwe Zangemeister-Wittke Methods for treating cancer using an immunotoxin
WO2005081898A2 (en) 2004-02-20 2005-09-09 The Trustees Of The University Of Pennsylvania Binding peptidomimetics and uses of the same
EP1867661A1 (en) * 2006-06-12 2007-12-19 Diatos Compositions and methods for delivering anti-activated ras antibodies into cells
US20090110662A1 (en) * 2007-04-30 2009-04-30 Intezyne Technologies, Inc. Modification of biological targeting groups for the treatment of cancer
WO2009089186A2 (en) 2008-01-05 2009-07-16 Sloan-Kettering Institute For Cancer Research Peptide-conjugated oligonucleotide therapeutic and method of making and using same
EP2352522A4 (en) * 2008-11-06 2014-03-05 Univ Washington BISPECIFIC AUXILIARIES FOR INTRA-CELLULAR RELEASE
US8241623B1 (en) * 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
US8481678B2 (en) * 2009-03-30 2013-07-09 E I Du Pont De Nemours And Company Peptide-based tooth whitening reagents
CN101724073A (zh) 2010-01-19 2010-06-09 成都军区昆明总医院 一种广谱抗ras基因表达蛋白的单克隆抗体及其制备方法
US8524220B1 (en) * 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US8362207B2 (en) * 2010-04-16 2013-01-29 Wake Forest University Health Sciences Multi-level specific targeting of cancer cells with IL-13
WO2012040513A1 (en) * 2010-09-22 2012-03-29 The Board Of Regents Of The University Of Texas System Compositions and methods for the delivery of beta lapachone
CA2816584A1 (en) * 2010-11-01 2012-05-10 Peptimed, Inc. Compositions of a peptide-based system for cell-specific targeting
US8515001B2 (en) * 2010-12-24 2013-08-20 Lg Display Co., Ltd. Shift register
EP2476441A1 (en) 2011-01-13 2012-07-18 Universitat Autònoma De Barcelona Methods and reagents for efficient and targeted delivery of therapeutic molecules to CXCR4 cells
US20120283410A1 (en) * 2011-03-14 2012-11-08 Intezyne Technologies, Incorporated Attachment of biological targeting groups using metal free click chemistry
US9062312B2 (en) * 2011-06-21 2015-06-23 Danisco Us Inc. Fusion peptides comprising multi-functional peptidic solubility tags for efficient production, processing and surface applications
US9572898B2 (en) * 2013-09-09 2017-02-21 Seton Hall University Functionalized fluorine containing phthalocyanine molecules
GB201318954D0 (en) * 2013-10-28 2013-12-11 Cupid Peptide Company Ltd Cell transport
PT3137605T (pt) 2014-05-01 2020-12-18 Ionis Pharmaceuticals Inc Composições e métodos para modulação da expressão de angiopoietina de tipo 3
WO2016022597A1 (en) 2014-08-04 2016-02-11 Case Western Reserve University Targeting peptides and methods of use
EP3226840B1 (en) 2014-12-17 2020-07-29 SRI International Antigen delivery system
US20180157388A1 (en) 2016-12-02 2018-06-07 Google Inc. Emotion expression in virtual environment
CA3047491A1 (en) 2016-12-21 2018-06-28 Bayer Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
CN118240025A (zh) 2017-07-10 2024-06-25 斯坦福国际研究院 用于治疗癌症的肽皂草素缀合物
US11965004B2 (en) 2017-07-10 2024-04-23 Sri International Molecular guide system peptides and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PLOS ONE，2013年，Vol.8, No.6, e66084，p.1-11
SCIENTIFIC REPORTS，2014年，Vol.4, No.1, Article number:4480，p.1-11

Also Published As

Publication number Publication date
JP2025081638A (ja) 2025-05-27
EP3652196A4 (en) 2021-08-18
AU2024227641A1 (en) 2024-11-14
US20240209041A1 (en) 2024-06-27
EP3652196A1 (en) 2020-05-20
JP7642700B2 (ja) 2025-03-10
JP2023085493A (ja) 2023-06-20
WO2019014190A1 (en) 2019-01-17
US12441774B2 (en) 2025-10-14
US20260015395A1 (en) 2026-01-15
AU2018301804A1 (en) 2020-01-30
US11965004B2 (en) 2024-04-23
CN111278847A (zh) 2020-06-12
CN111278847B (zh) 2024-04-19
CN118221770A (zh) 2024-06-21
JP2020535110A (ja) 2020-12-03
AU2018301804B2 (en) 2024-07-25
US20220227823A1 (en) 2022-07-21
AU2026201731A1 (en) 2026-03-26
AU2024227641B2 (en) 2025-12-18

Similar Documents

Publication Publication Date Title
JP7289029B2 (ja) 分子誘導システムペプチド及びその使用
JP5603145B2 (ja) 疾患のイメージング、診断、及び治療
US12576157B2 (en) Peptide saporin conjugate for the treatment of cancer
CN101160321A (zh) Q3 sparc缺失突变体及其用途
AU2020357455B2 (en) Molecular guide system peptides and uses thereof
JP2011200233A5 (https=)
US10925968B2 (en) Cell internalizing compounds
TW202535920A (zh) 程序性死亡配體1（pd-l1）嵌合抗原受體及其應用
WO2004029089A2 (fr) Nouvelle cible de l’ angiogenese et utilisations

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210712

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221107

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230307

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20230406

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230421

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230421

R150 Certificate of patent or registration of utility model

Ref document number: 7289029

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150